... drug therapy Prednisone Eculizumab ...
"Like You" Patient Story last updated 04/05/2017 - 1:27pm.
... fight foreign invaders, such as viruses, in the body. Eculizumab (Soliris®) compensates for the CD59 but not the CD55 deficiency in people with PNH. But many patients treated with eculizumab have C3 (a protein in the complement system) on the surface of their ...
Research Review last updated 05/02/2016 - 9:21am.
... By far the biggest advance was the FDA approval of eculizumab (Soliris®), which has radically changed treating the disease. ...
Interview last updated 09/23/2016 - 2:33pm.
... patients with PNH will have only a partial response to eculizumab , in that they will still be anemic and dependent upon transfusions. In some cases this will be because eculizumab only partially blocks the complement proteins. It turns out that ...
Research Review last updated 05/02/2016 - 9:25am.
... Criteria: Prior use of eculizumab (Soliris®) within 3 months of entry is prohibited Any other ...
Clinical Trial last updated 09/14/2016 - 10:39am.
... <38.0 kg/m2 Diagnosed with PNH On treatment with eculizumab (Soliris®) for at least 3 months Hb < 10 g/dL at screening ...
Clinical Trial last updated 08/24/2016 - 11:15am.
...
Page last updated 03/14/2016 - 6:05pm.
... of diagnosis and following therapy with C5 inhibitor ( Eculizumab ). PBMCs from these patients are stored as viable cells and being ... 5 PNH patients have been stained and analysed pre and post Eculizumab by the same method (10 samples) and the preliminary data suggest ...
Grant Recipient last updated 08/02/2016 - 3:35pm.
... a brief discussion about how complement inhibitors like Eculizumab can work to reduce or stop complement activation. As with all of ...
LMS Item last updated 06/10/2016 - 1:24pm.
... experience. She also covers treatment options, including eculizumab , immunosuppressive drug therapy , stem cell ...
LMS Item last updated 06/10/2016 - 1:24pm.